Outlook Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for OTLK, updated each market day.
OTLK AI Sentiment
AI predicts Outlook Therapeutics, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Sector
Exchange
Market Cap
$23,245,279
Cap Tier
Employees
17
Headquarters
ISELIN, NJ
Listed Since
May 13, 2016
OTLK Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
OTLK Volatility
Outlook Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
